ONYX PHARMACEUTICALS INC 4

4 · ONYX PHARMACEUTICALS INC · Filed Jul 2, 2013

Form 4

Period: 2013-07-01

VP, Corp. Communication/I.R.

Transactions

Exercise/Conversion
Common Stock
2013-07-01$30.28/sh+765$23,164→ 20,139 total
Exercise/Conversion
Stock Option (Right to Buy)
2013-07-01−765→ 5,104 total
Exercise: $30.28Exp: 2020-03-31→ Common Stock (765 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2013-07-01−719→ 16,291 total
Exercise: $37.68Exp: 2022-03-29→ Common Stock (719 underlying)
Exercise/Conversion
Common Stock
2013-07-01$37.68/sh+719$27,092→ 21,405 total
Sale
Common Stock
2013-07-01$132.63/sh−2,304$305,580→ 19,374 total
Exercise/Conversion
Stock Option (Right to Buy)
2013-07-01−547→ 8,021 total
Exercise: $35.18Exp: 2021-03-31→ Common Stock (547 underlying)
Exercise/Conversion
Common Stock
2013-07-01$35.18/sh+547$19,243→ 20,686 total
Exercise/Conversion
Stock Option (Right to Buy)
2013-07-01−273→ 0 total
Exercise: $28.55Exp: 2019-03-31→ Common Stock (273 underlying)
Exercise/Conversion
Common Stock
2013-07-01$28.55/sh+273$7,794→ 21,678 total

Holdings

Footnotes (3)

[F1]Shares sold pursuant to a 10b5-1 plan.
[F2]12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months.
[F3]Fully vested.

Documents

1 file